Charles River Laboratories Executive Sells $742K in Shares Under 10b5-1 Plan

Executive Summary

On October 23, 2026, Charles River Laboratories International, Inc. ($CRL) filed a Form 4 disclosing that Shannon M. Parisotto, Corporate Executive Vice President, Discovery & Safety Assessment, executed a routine stock option exercise and subsequent sale on October 21, 2026.

Transaction Details

• Stock Option Exercise: Exercised 2,156 options with an exercise price of $244.41 per share (expiring May 27, 2032).
• Open-Market Sale: Sold 2,156 shares of Common Stock at $344.41 per share, generating gross proceeds of $742,547.96.
• Pre-Arranged Plan: Footnotes indicate the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026.

Post-Transaction Holdings

Following the transactions, Shannon M. Parisotto holds:

• Direct Ownership: 4,807 shares of Common Stock.
• Indirect Ownership:
  • 28,510 shares held through Karpathos Investments LLC.
  • 9,680 shares held through a Trust.
• Derivative Holdings: 719 remaining stock options exercisable at $244.41.

Market & Governance Context

The transaction represents a standard "exercise-and-sell" program under an established Rule 10b5-1 plan. Because the transaction was planned months in advance and the insider retains substantial direct and indirect equity exposure (over 42,900 total shares), this transaction carries Low trading significance and does not reflect a change in executive sentiment.